Keil, Andreas; Frese-Schaper, Manuela; Steiner, Selina; Körner, Meike; Schmid, Ralph; Frese, Steffen R. (2015). The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis. Arthritis & rheumatology, 67(7), pp. 1858-1867. Wiley-Blackwell 10.1002/art.39119
![]() |
Text
Keil 2015 Arthritis Rheumatology.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (515kB) |
OBJECTIVE
The treatment of lupus nephritis is still an unmet medical need requiring new therapeutic approaches. Our group found recently that irinotecan, an inhibitor of topoisomerase I (topo I), reversed proteinuria and prolonged survival in mice with advanced lupus nephritis. While irinotecan is known to stabilize the complex of topo I and DNA, the enzyme tyrosyl-DNA phosphodiesterase 1 (TDP-1) functions in an opposing manner by releasing topo I from DNA. Therefore, we undertook this study to test whether the TDP-1 inhibitor furamidine has an additional effect on lupus nephritis when used in combination with irinotecan.
METHODS
NZB/NZW mice were treated with low-dose irinotecan and furamidine either alone or in combination beginning at age 26 weeks. DNA relaxation was visualized using gel electrophoresis. Binding of anti-double-stranded DNA (anti-dsDNA) antibodies to DNA modified by topo I, TDP-1, and the topo I inhibitor camptothecin was determined by enzyme-linked immunosorbent assay.
RESULTS
Compared to treatment with either agent alone, simultaneous treatment with low-dose irinotecan and furamidine significantly improved survival of NZB/NZW mice. Similar to what has been previously shown for irinotecan alone, the combination treatment did not change the levels of anti-dsDNA antibodies. In vitro, recombinant TDP-1 increased topo I-mediated DNA relaxation, resulting in enhanced binding of anti-dsDNA antibodies. In combination with topo I and camptothecin, TDP-1 reversed the inhibitory effects of camptothecin on DNA relaxation and anti-dsDNA binding.
CONCLUSION
Affecting DNA relaxation by the enzymes topo I and TDP-1 and their inhibitors may be a promising approach for the development of new targeted therapies for systemic lupus erythematosus.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Mu50 > Forschungsgruppe Thoraxchirurgie 04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Thoracic Surgery |
Graduate School: |
Graduate School for Cellular and Biomedical Sciences (GCB) |
UniBE Contributor: |
Keil, Andreas, Frese-Schaper, Manuela, Steiner, Selina Katja, Schmid, Ralph, Frese, Steffen R. |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2326-5205 |
Publisher: |
Wiley-Blackwell |
Language: |
English |
Submitter: |
Thomas Michael Marti |
Date Deposited: |
04 Apr 2016 12:15 |
Last Modified: |
02 Mar 2023 23:27 |
Publisher DOI: |
10.1002/art.39119 |
PubMed ID: |
25779651 |
BORIS DOI: |
10.7892/boris.77756 |
URI: |
https://boris.unibe.ch/id/eprint/77756 |